Role of miRNA and RNA binding proteins (RNA-BPs) in the regulation of the autophagy signalling pathway in ALK dependent tumours

The Cancer Research Centre of Toulouse (CRCT)

Dr. Sylvie Giuriato


Publication Link ORCID Link

RNA biology in hematological cancers

Research Interest

Dr Sylvie Giuriato has focused recently on the role of autophagy following crizotinib therapy in ALK-positive ALCL. The goal is to pursue understanding the role and the regulation (in particular post-transcriptional regulation through microRNAs and/or RNA-Binding proteins) of this process in different ALK-positive tumours, both in basal conditions and following targeted-, chemo- and immuno-therapies.

Domenico Sorrentino

Research student



Research Interest

I received a master degree (MSc) in Pharmaceutical Biotechnology from University of Bologna and an Integrated master’s degree in Drug design and development from University of Pavia. I performed a traineeship in oncolytic virus field at DKFZ of Heidelberg.  My professional interests focus on cancer research, particularly, on combinatorial treatments modulation.  In addition, I will realize as PhD student for ALKATRAS consortium my next project that will concern the Role and regulation of autophagy in ALK dependent tumors.

Research description

A wide array of deregulated miRNAs has previously been defined by a number of ERIA members in ALK-induced malignancies and has potential diagnostic utility. Since the miRNA targeted sequences and the RNA-BP binding sites are often close or overlapping, the question of cross-talk between these two RNA modulators will be investigated in terms of classical (proliferation, survival, invasion) and emerging (autophagy, ER Stress) mechanisms of tumorigenesis.

We specifically aim to: Investigate the regulation of autophagy signalling by miRNAs and RNA-BPs or epigenetic modifications; determine the role of autophagy, using classical autophagy assays, in ALCL, NSCLC and neuroblastoma cell lines and mouse models; test whether autophagy inhibition can potentiate the efficacy of ALK inhibition by Crizotinib and other second generation inhibitors.

Expected Results:
Identification of the regulatory network of autophagy in ALK+ malignancies; optimize current ALK therapies by interfering with autophagy-related pathways; develop of biomarkers to predict therapy response in ALK+ patients

Planned secondment(s):
Year 1: Sofigen (PO#10) – analysis of epigenetic modifications in ALCL – 1 month;
Year 2:Tuebingen (B#5)- analysis of miRNA and downstream signalling pathways – 2 months

Blog posts:

Latest publication: